PAI-1 and atherothrombosis

Douglas E. Vaughan*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

392 Scopus citations


Plasminogen activator inhibitor-1 (PAI-1) is the major physiologic inhibitor of tissue-type plasminogen activator in plasma, and is elevated in a variety of clinical situations that are associated with increased risk of ischemic cardiovascular events. Recent insights into the biology of PAI-1 suggest that it is more than just an innocent bystander in the pathogenesis of ischemic heart disease. Elevated PAI-1 levels appear to increase the risk of atherothrombotic events and may also promote the progression of vascular disease. The development and testing of specific PAI-1 antagonists will enable basic and clinical investigators the opportunity to test the hypothesis that vascular PAI-1 excess promotes the development of intravascular thrombosis and atherosclerosis.

Original languageEnglish (US)
Pages (from-to)1879-1883
Number of pages5
JournalJournal of Thrombosis and Haemostasis
Issue number8
StatePublished - 2005


  • Fibrinolysis
  • Inhibitor-1
  • Plasminogen activator
  • Risk factors
  • Thrombosis

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'PAI-1 and atherothrombosis'. Together they form a unique fingerprint.

Cite this